Attorney Docket No.: PB60228USw

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Demont et al. Confirmation No : 1065 Serial No.: 10/553.878 Group Art Unit: 1615 Filing Date: October 17, 2005 Examiner: (not yet assigned) For: TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR §1.97. [X] Copies of the references are attached. Copies of the references were submitted in parent application Serial No. . (37 CFR §1.98(d)). A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449, and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. (37 CFR §1.97(b)). OR The Information Disclosure Statement submitted herewith is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR §1.114. (37 CFR §1.97(b)(4)). В The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in §1.491 of an international application or after the mailing date of the first Office Action on the merits. whichever event occurred last, but before the mailing date of either: a final Office Action under §1.113 or a Notice of Allowance under §1.311,

whichever occurs first

Attorney Docket No.: PB60228USw

	[	1	Applicant hereby certifies that each item of information contain information Disclosure Statement was cited in a communication foreign patent office in a counterpart foreign application not me months prior to the filing of this statement.	on from a	
	[	1	Applicant elects the option to pay the fee set forth in 37 CFR § submission of an Information Disclosure Statement under §1.91.000).		
C.	Į.	1	The Information Disclosure Statement transmitted herewith is after a final Office Action under §1.113, or a Notice of Allowar §1.311, whichever occurs first, but before the payment of the inenclosed is a copy of the International Search Report which is International Publication No.	ssue fee. Also	
In accordance with the requirements of 37 CFR §1.97(d):					
	[	] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.			
	0	R			
	I	]	] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information containe in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; and		
	[	]	The petition fee set forth in §1.17(i)(1) (\$180.00) is submitted	herewith.	
[X] []		Please charge any required fees to Deposit Account No. <u>07-1392</u> . A duplicate copy of this paper is attached.			
			Respectfully Submitted,		
			Lonnie L. Deppenbrock Bonnie L. Deppenbrock Attorney of Record	<u>-</u>	
Glaxo Corpo 5 Moo Resea Telep	orat orat ore arcl	r No nithK e Int Drive n Tria ne: (9	Registration No. 28,209  6. 23347  Kline ttellectual Property ve, P.O. Box 13398 riangle Park, NC 27709-3398 (919) 483-1577 (919) 483-7988		